)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Sarepta Therapeutics
Sarepta Therapeutics (SRPT) investor relations material
Sarepta Therapeutics Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary8 Jun, 2026
Leadership transition and organizational outlook
CEO announced retirement by year-end, with an active succession process underway and commitment to a smooth transition.
No current transition activities; leadership remains focused on executing strategic priorities.
Strategic priorities and financial position
Priorities for 2026 include stabilizing ELEVIDYS, advancing the pipeline, and strengthening financials.
Organization is cash flow positive and profitable, with cash expected to exceed $900 million.
Sales guidance for the year is $1.2–$1.4 billion, with cost structure just over $800 million.
Pipeline and commercial execution
Five siRNA therapies are dosing in the clinic, with additional programs in research.
Success in sales guidance range is driven by ELEVIDYS performance and promotional activities.
Expanded sales force and patient education initiatives are increasing reach and engagement.
Explain siRNA platform differentiation from TFR
What is the primary endpoint for Cohort 8?
How will you defend EXONDYS against Dyne?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sarepta Therapeutics
- Record revenue and profitability in 2024, with 68–70% growth targeted for 2025.SRPT
Q4 20249 Jul 2026 - Shipments and dosing for non-ambulatory patients suspended after two fatal liver failure cases.SRPTStatus Update9 Jul 2026
- Two-year results confirm durable efficacy, safety, and support for early intervention in DMD.SRPTStatus Update9 Jul 2026
- Q3 2024 revenue up 41%, profitability achieved, and PPMO program discontinued.SRPTQ3 20249 Jul 2026
- ELEVIDYS gene therapy provides sustained functional benefit and slows Duchenne progression by up to 73% over 3 years.SRPTStudy result8 Jul 2026
- Q2 revenues surged 51% to $360.5M, with strong ELEVIDYS and PMO product performance.SRPTQ2 20248 Jul 2026
- All proposals passed amid board focus on stability, CEO succession, and performance improvement.SRPTAGM 20264 Jun 2026
- Q1 2026 delivered strong profitability, positive cash flow, and reaffirmed FY 2026 guidance.SRPTQ1 20267 May 2026
- Proxy seeks approval for director elections, compensation, equity plans, and auditor ratification.SRPTProxy filing24 Apr 2026
Next Sarepta Therapeutics earnings date
Q2 20265 Aug, 2026
Sarepta Therapeutics
Next Sarepta Therapeutics earnings date
Q2 20265 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage